Proline Compounds as Selective Granzyme B Inhibitors
Solution Overview
Problem
Current Granzyme B inhibitors are either nonspecific, costly to manufacture, or present drug delivery challenges, lacking selectivity and simplicity in addressing Granzyme B-related diseases and conditions.
Innovation Solution
Development of Granzyme B inhibitor compounds with specific chemical formulas (I, II, and III) that include stereoisomers, tautomers, and pharmaceutically acceptable salts, designed to inhibit Granzyme B effectively with ease of manufacture and administration, including topical, oral, and injection routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonspecific inhibitors such as isocoumarins are used, then inhibition of Granzyme B is achieved, but selectivity and potency are insufficient
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features (proline core structure with particular substituent patterns) that confer selectivity for Granzyme B over other serine proteases. The compounds have specific structural characteristics at key positions that match the Granzyme B active site geometry, enabling selective binding while maintaining potent inhibition.
2Reliability
If biological inhibitors such as serpins are used, then Granzyme B inhibition is achieved, but manufacturing cost and delivery challenges increase
Solution Approach 1:
The patent employs small molecule chemical compounds with simple synthetic routes and stable structures that can be manufactured cost-effectively. These synthetic inhibitors replace expensive biological inhibitors (serpins) with chemically synthesized proline-based compounds that are more stable, easier to store, and less costly to produce at scale.
3Reliability
If tricyclic inhibitors are used, then Granzyme B inhibition is achieved, but synthetic complexity and manufacturing cost increase due to complex core structure
Solution Approach 1:
The patent extracts and simplifies the essential inhibitory features from complex tricyclic inhibitors by focusing on a proline core structure with selective substituent placement. This extracted simplified structure maintains Granzyme B binding capability while eliminating the synthetic complexity and manufacturing difficulties associated with tricyclic frameworks.
4Reliability
If tricyclic inhibitors are used, then Granzyme B inhibition is achieved, but water solubility decreases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical properties of the inhibitor molecules through selective substitution on the proline core. By introducing polar or ionizable groups at specific positions, the compounds achieve improved water solubility while maintaining their Granzyme B inhibitory activity, thus resolving the solubility problem of earlier inhibitors.
Data Source
AI summary
Proline compounds as Granzyme B inhibitors, compositions that include the compounds, and methods for using the compounds. Methods for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided.